skip to content

Maxwell Centre

Event Type: 
Core programme events

Innovation Seminar Series Talk - online

"SMARTer health-tech"

*SMART = Specific, Measurable, Achievable, Relevant, and Time-Bound
Dr Gita Dr Gita Khalili Moghaddam, researcher in the Department of Clinical Neurosciences, University of Cambridge, CEO and founder of TumourVue and GlycoVue


About the Speaker

Gita obtained her PhD in Biotechnology from the University of Cambridge in 2017. She is currently on secondment at GSK Global Health until 2023 as a UKRI Innovation Scholar, taking a leading role in the use of AI in tuberculosis drug development. Gita co-founded TumourVue Ltd in 2018 and GlycoVue Ltd in 2019.

In 2019, Gita was awarded a prestigious Borysiewicz Biomedical Sciences Fellowship at the University of Cambridge in recognition of her outstanding research in the field of biomedical engineering. As an academic entrepreneur, she has been widely recognised as one of the top 18 women in AI & Data by Innovate UK (2019), a BioBeat Mover & Shaker in BioBusiness (2020), top contender for Cofinitive 21toWatch (2021). Gita was recently awarded as "Business Woman of the Year" and as "Best New Business" with her venture GlycoVue by the SME Cambridgeshire Business Awards 2021.


About the Company

TumourVue is a disruptive imaging technology for cancer treatment. The delineation of tumour margins is challenging due to existing technical limitations. TumourVue’s innovative solution is a real-time imaging platform where AI creates a colour-coded image of precise tumour margins, superimposed on the surgeon’s eye during operation, to reduce the risk of local recurrence, improve survival rates and reduce treatment costs.

GlycoVue represents the accumulation of more than 15 years of experimental research in near-continuous glucose monitoring in readily accessible biological fluids. GlycoVue combines glucose-responsive smart polymers with advanced holography and AI-enabled smartphone-based instrumentation to create a platform for diabetes self-management. We have fabricated a transparent glucose-sensitive hologram using in-house synthesised boronate monomers as the selective glucose receptors. Preliminary in vitro assessment of its sensitivity, stability and performance appears promising. A smartphone is used to quantify the colour response of the hologram with an appropriate algorithm and convert it into the blood glucose concentration. GlycoVue has the potential to revolutionise diabetes management by launching a glucose measurement system which would potentially lead to better adherence to glucose self-monitoring and therefore ameliorate the complications of diabetes. This will improve the life quality of >425M people with diabetes and potentially halve diabetes-related healthcare costs. The glucose self-monitoring market is expected to reach US$32.3B by 2024 with a CAGR of 6.2% from 2016. Our team covers expertise across the value chain, is well-balanced and autonomous, and has unique complementary skills to deliver and exploit the technology."

Both ventures are spin-offs from the University of Cambridge.



About the Seminar Series

This series of seminars happen monthly and speaker will present their ideas and experiences on how innovation impacts their endeavours. 

  • We have a varied list of speakers, from academics turned in to entrepreneurs all the way to established companies. 
  • The format is a 45 minute talk, followed by Q&A
  • Attendance is free 

Come and join the talk with Jeremy. Please register for the event here or send an email to

Wednesday, 9 March, 2022 - 16:00 to 17:30
Contact name: 
Dr Alexandra Huener
Event location: 
Zoom event